^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Pancreatic Adenocarcinoma
    Drug:Krazati (adagrasib) (KRAS G12C inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    05/04/2023
    Excerpt:
    Pancreatic Adenocarcinoma….PRINCIPLES OF SYSTEMIC THERAPY….Useful in Certain Circumstances...Adagrasib (if KRAS G12C mutation positive)
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Title:

    Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

    Excerpt:
    Mirati Therapeutics...announced the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization approval for KRAZATI® (adagrasib) as a monotherapy indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRASG12C mutation and have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.